Antimicrobial Resistance Patterns and Serological Diversity of Shigella Species from Patient Isolates at University Teaching Hospital in Lusaka, Zambia
Authors:
- Mike NundweMNMike Nundwe
- Joseph Yamweka ChizimuJCJoseph Yamweka Chizimu
- John MwabaJMJohn Mwaba
- Misheck ShawaMSMisheck Shawa
- Rodrick S. KateteRKRodrick S. Katete
- Mable Mwale MutengoMMMable Mwale Mutengo
- Ruth NakazweRNRuth Nakazwe
- Namwiinga R. MulundaNMNamwiinga R. Mulunda
- Cephas SialubanjeCSCephas Sialubanje
- Mox Malama KalumbiMKMox Malama Kalumbi
- Yamba KaundaYKYamba Kaunda
- Rapheal ChandaRCRapheal Chanda
Open Access
Abstract
Background: Shigella species are the leading cause of human shigellosis. In Zambia, more than 30% of children experiencing diarrhea are infected with Shigella species. The increasing resistance of Shigella species to the recommended therapy is of great concern. Therefore, this study investigated the antibiotic resistance profiles and phenotypic and genotypic characteristics of Shigella isolates at the largest referral hospital in Zambia. Methodology: Of the forty-eight archived presumptive Shigella isolates, thirty-two were serologically confirmed and subjected to antimicrobial susceptibility testing using the Kirby Bauer disk diffusion method. Thereafter, polymerase chain reaction was performed to detect the bla genes. Results: Most isolates were Shigella flexneri (16/32, 50%) and Shigella sonnei (14/32, 44%), while Shigella boydii and Shigella dysenteriae were rare. High resistance rates were noted for sulfamethoxazole/trimethoprim (78%) and tetracycline (75%), while 15.6% of the isolates showed resistance to ciprofloxacin and/or azithromycin. The blaTEM gene encoding beta-lactamase was detected in 7/32 (22%) of isolates. Conclusions: In this study, a significant number of multidrug-resistant isolates were identified. Additionally, Shigella species resistant to the World Health Organization-recommended drugs call for strengthened laboratory diagnosis and close monitoring of these pathogens to guide the clinical management of shigellosis.Keywords
Funding Information
- Japan Agency for Medical Research and Development (AMED) (JP23wm0125008, JP233fa627005)
This publication has 41 references indexed in Scilit:
- Current rates of purchasing of antibiotics without a prescription across sub-Saharan Africa; rationale and potential programmes to reduce inappropriate dispensing and resistanceExpert Review of Anti-infective Therapy, 2023
- Menace of antimicrobial resistance in LMICs: Current surveillance practices and control measures to tackle hostilityJournal of Infection and Public Health, 2022
- Antimicrobial resistance in low- and middle-income countries: current status and future directionsExpert Review of Anti-infective Therapy, 2021
- Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidencePaediatrics and International Child Health, 2018
- The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteinsProteomics, 2009
- Third-generation cephalosporinsMedical Clinics of North America, 1995
- Is protection against shigellosis induced by natural infection with Plesiomonas shigelloides?The Lancet, 1994
- Inoculum Size in Shigellosis and Implications for Expected Mode of TransmissionThe Journal of Infectious Diseases, 1989
- Pathophysiology of Shigella Diarrhea in the Rhesus Monkey: Intestinal Transport, Morphological, and Bacteriological StudiesGastroenterology, 1975
- History of SulfonamidesJAMA Otolaryngology–Head & Neck Surgery, 1966